Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 341 results found since Jan 2013.
The Other Opioid Crisis: Hospital Shortages Lead To Patient Pain, Medical Error
I came across this public-accesss story, and wanted to share the perspective:
Pauline Bartolone, Kaiser Health News
Even as opioids flood American communities and fuel widespread addiction, hospitals are facing a dangerous shortage of the powerful painkillers needed by patients in acute pain, according to doctors, pharmacists and a coalition of health groups.
The shortage, though more significant in some places than others, has left many hospitals and surgical centers scrambling to find enough injectable morphine, Dilaudid and fentanyl — drugs given to patients undergoing surgery, fighting cancer or suffering traumatic i...
Source: Suboxone Talk Zone - March 26, 2018 Category: Addiction Authors: admin Tags: Acute Pain Anesthesia Public policy surgery Chronic pain opioid addiction Source Type: blogs
Hospitalized Patients Are Civilian Casualties in the Government ' s War on Opioids
A recentstory by Pauline Bartolone in the Los Angeles Times draws attention to some under-reported civilian casualties in the government ’s war on opioids: hospitalized patients in severe pain, in need of painkillers. Hospitals across the country are facing shortages of injectable morphine, fentanyl, and Dilaudid (hydromorphone). As a result, trauma patients, post-surgical patients, and hospitalized cancer patients frequently go un dertreated for excruciating pain.Hospitals, including the ones in which I practice general surgery, are working hard to ameliorate the situation by asking medical staff to use prescription opi...
Source: Cato-at-liberty - March 18, 2018 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs
FDA approves new drug for men at high risk of prostate cancer spread
A newly approved drug called apalutamide is giving hope to thousands of men confronting a tenacious problem after being treated for prostate cancer. Prostate-specific antigen (PSA) levels should plummet to zero after surgery, and to near zero after radiation therapy, but in some men, they continue rising even when there’s no other evidence of cancer in the body. Doctors typically respond to spiking PSA with drugs that block the production of testosterone, which is the male sex hormone that fuels prostate cancer. However, this type of medically induced castration, called hormonal therapy, doesn’t always reduce PSA. More...
Source: Harvard Health Blog - March 15, 2018 Category: Consumer Health News Authors: Charlie Schmidt Tags: Cancer Health Men's Health Prostate Health Source Type: blogs
The War on Opioids Has Become a War on Patients
As Anne Fuqua recentlypointed out in the Washington Post, non-medical drug users accessing heroin and fentanyl in the underground drug market are not the only victims in the opioid crisis. Many patients whose only relief from a life sentence of torturing pain are also victims. That is because policymakers continue to base their strategies on the misguided and simplistic notion that the opioid overdose crisis impacting the US,Canada, andEurope, is tied to doctors prescribing opioids to their patients in pain.Unfortunately, political leaders and the media operate in an echo chamber, reinforcing the notion that cutting back o...
Source: Cato-at-liberty - March 12, 2018 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs
New Treatment for Breast Cancer Could Help Some Women Avoid Surgery
Most women diagnosed with early stage breast cancer typically have surgery to remove the tumor, followed by three to six weeks of radiation. But there’s an exciting new development in breast cancer treatment – a first-of-its kind radiation therapy system for early stage cancers that may cut the number of treatments to only a few days.
And, one day, the inventors say, it might even eliminate the need for surgery altogether for some patients.
It’s called the GammaPod, invented by scientists at the University of Maryland School of Medicine. The U.S. Food and Drug Administration (FDA) recently cleared the way for the Gam...
Source: Life in a Medical Center - February 20, 2018 Category: Universities & Medical Training Authors: UMMC Admin Tags: Cancer breast cancer cancer treatment Cedric X. Yu Elizabeth Nichols GammaPod UMMC Source Type: blogs
Inspirata Acquires Omnyx from GE Healthcare, Achieving an End-to-End Solution
The business model of Inspirata is relatively unique compared to other companies connected to digital pathology. The company seeks to enhance the digital pathology workflow of its clients presumably pathology departments and consulting firms. Here is a summary of the company goals copied from the company web page (WELCOME TO INSPIRATA):We...help cancer institutions overcome the financial barriers to adoption using our unique business and delivery model where we make the upfront capital investment in the hardware, software and storage needed to enable a cancer institution to move to a fully automated digital pathology...
Source: Lab Soft News - February 7, 2018 Category: Laboratory Medicine Authors: Bruce Friedman Tags: Digital Imaging in Pathology Food and Drug Administration Lab Industry Trends Lab Processes and Procedures Lab Regulation Pathology Informatics Surgical Pathology Source Type: blogs
Farewell Pharma Friends! Beware of the PharmaGovernment Complex!
It ' s my 71st birthday and I decided it ' s a good time for me to move on to a new role. Unbelievable, right? John " PharmaGuy " Mack is seventy-one years old!Also unbelievable is that I am shuttering my pharmaceutical online publishing business after 16 years of continuous operation! There will be no more Pharma Industry News Update emails, no more PharmaGuy Insights on Scoop.it, and no new Pharma Marketing Blog posts. There will still be tweets from @pharmaguy, but eventually even that will end.Although one door has closed, another door has opened for me as a Newtown Township, PA Supervisor. Yes, I am now a “pol...
Source: Pharma Marketing Blog - February 6, 2018 Category: Pharmaceuticals Source Type: blogs
How to Cope with a Scary Medical or Mental Health Diagnosis
Most of us are sanguine about the fact that some things are out of our control. We know, for example, that we can’t avoid death or taxes or do much about how tall we’ll grow. For much of everything else, we figure out a way to deal with what happens in life — until we can’t, for one reason or another. A prime example is the emotional upheaval caused by receiving an unexpected and scary medical or mental health diagnosis. Having gone through this myself recently, here are some ways to help you cope.
Get all the facts.
After the initial shock, take a few deep breaths and resolve to learn as much as you can about ...
Source: World of Psychology - January 29, 2018 Category: Psychiatry & Psychology Authors: Suzanne Kane Tags: Anxiety and Panic Grief and Loss Health-related Inspiration & Hope Motivation and Inspiration Cancer Chronic Illness Coping Skills health scare Medical Care Mental Illness Resilience Source Type: blogs
Hospital Groups Plan to Launch a Company to Manufacture Generic Drugs
Manufacturers of generic drugs likeTeva Pharmaceutical have been suffering serious financial reverses (see: Teva warns on profit as drugmaker's problems deepen). Moreover, periodic shortages of generic drugs have been exacerbated by the fact that some of them are manufactured by only one company (see:New Study Highlights Escalated Dangers of Generic Drug Shortages). Here is a quote from this article:In 2011, 251 drug shortages occurred, 73% of which were generic sterile injectables that served as treatments for sepsis, cancer, and other life-threatening illnesses. In February 2011, the FDA announced a severe nati...
Source: Lab Soft News - January 27, 2018 Category: Laboratory Medicine Authors: Bruce Friedman Tags: Food and Drug Administration Healthcare Business Healthcare Innovations Hospital Executive Management Pharmaceutical Industry Quality of Care Source Type: blogs
BioViva Illustrates the Tension Between Progress and Regulation
Elizabeth Parrish of BioViva, you might recall, has made every effort to publicize the follistatin and telomerase gene therapy that she underwent. This is a strategy intended to accelerate progress; I suspect she was not the first, and that others were just more circumspect. The technology exists, it is not expensive in the grand scheme of things, and at the very least hundreds of people have the laboratory access and the knowledge to carry out such an operation. BioViva's efforts, and those of other ventures such as the Odin and Ascendance Biomedical illustrate the tension between desire for progress and desire for regula...
Source: Fight Aging! - December 27, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
The 10 Most Exciting Digital Health Stories of 2017
Gene-edited human embryo. Self-driving trucks. Practical quantum computers. 2017 has been an exciting year for science, technology – and digital health! It’s that time of the year again when it’s worth looking back at the past months; and list the inventions, methods and milestone events in healthcare to get a clearer picture what will shape medicine for the years to come.
2017 – Amazing year for science and healthcare
Scientists, researchers, and innovators come up with amazing breakthroughs every year, and that was no different in 2017 either. No matter whether we look at physics (proving the existence of gra...
Source: The Medical Futurist - December 13, 2017 Category: Information Technology Authors: nora Tags: Future of Medicine 3d printing artificial intelligence digital health genetics genomics Healthcare Innovation Personalized medicine robotics technology wearables Source Type: blogs
ICER Expanding Probe
A nonprofit group, the Institute for Clinical and Economic Review (ICER), recently received a three-year $13.9 million grant from the Laura and John Arnold Foundation to expand its ongoing investigative scope on drug pricing to include all new medicines and price increases on existing treatments.
Up until now, ICER hasn’t had the resources to review all new medicines. The additional funding “puts us on a new trajectory,” according to Steven D. Pearson, president of ICER. “Now we’re going to be able to cover the landscape.”
ICER was essentially founded with a $5.3 million grant from the Arnold Foundation in 20...
Source: Policy and Medicine - November 21, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Sensus Healthcare ’s Technology Uses Low-Energy X-rays Directly on Cancer Cells: Interview with CEO Joe Sardano
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - November 20, 2017 Category: Medical Devices Authors: Alice Ferng Tags: Dermatology Exclusive Oncology Source Type: blogs
MSK-IMPACT: New Tumor Profiling Genetic Test Approved by the FDA
Memorial Sloan Kettering Cancer Center has developed the first tumor-profiling laboratory developed test (LDT) approved by the FDA. It's called MSK-IMPACT. Below are some details about the test from a recent article (see:FDA Authorizes MSK-IMPACT Test for Analyzing Patient Tumor):The FDA ’s authorization of MSK-IMPACT sets a precedent for future authorization of tests developed by both academic and commercial labs....The test was developed by Memorial Sloan Kettering’s Department of Pathology to look for genetic mutations and other alterations in patients’ tumors.....MSK-IMPACT, which stands for integrated ...
Source: Lab Soft News - November 18, 2017 Category: Laboratory Medicine Authors: Bruce Friedman Tags: Clinical Lab Industry News Clinical Lab Testing Food and Drug Administration Lab Industry Trends Lab Processes and Procedures Medical Research Source Type: blogs
